Larotaxel: Broadening the road with new taxanes

Expert Opinion on Investigational Drugs

Volumn 18, Issue 8, 2009, Pages 1183-1189

  Metzger Filho, Otto ^b   Moulin, Camilo ^b   De Azambuja, Evandro ^a   Ahamad, Awada ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Jules Bordet Institute ^*

Author keywords

Larotaxel; RPR 109881A; Taxanes; Taxoids

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; LAROTAXEL; NAVELBINE; PACLITAXEL; RPR 109881A; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLADDER CANCER; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GLIOBLASTOMA; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MYALGIA; NAIL DISEASE; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; UROGENITAL TRACT CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 68049131597     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903119167     Document Type: Review

References (42)

1. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. New Engl J Med 2007;357(1):39-51
2. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17(5):735-49
3. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14(22):7167-72
4. Kurata T, Shimada Y, Tamura T, et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 2000;18(17):3164-71
5. Gelmon KA, Latreille J, Tolcher A, et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 2000;18(24):4098-108
6. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61
7. Wils P, Phung-Ba V, Warnery A, et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994;48(7):1528-30
8. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Nat Acad Sci USA 2005;102(23):8315-20
9. Pusztai L, Jeong J, Gong Y, et al. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Program and abstracts of the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Texas. Abstract 54
10. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007;18(Suppl 12):xii15-20
11. Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37(13):1590-8
12. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Investig New Drugs 2001;19(2):125-41
13. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23(31):7785-93
14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665-7
15. Gelfand VI, Bershadsky AD. Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 1991;7:93-116
16. Nogales E, Whittaker M, Milligan RA, Downing KH. High-resolution model of the microtubule. Cell 1999;96(1):79-88
17. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001;7(13):1213-28
18. Marie-Christine Bissery PV, Cécile Combeau, Jean-François Riou, et al. Preclinical evaluation of XRP9881A, a new taxoid [abstract 5430]. Amer Assoc Cancer Res 2004:1253-a [abstract]
19. Vrignaud P, Lejeune P, Bissery MC, et al. LaM-CB. In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid [abstract 3414]. Amer Assoc Cancer Res 2005
20. Patricia Vrignaud MC, Murray Stackhouse, Claudia Zuany-Amorim, et al. In vivo synergy between trastuzumab (herceptin®) and larotaxel (RPR 109881A), a new taxoid. AACR Meeting, abstract 1432 2007
21. Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 2002;13(7):1140-50
22. Dieras V, Limentani S, Romieu G, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008;19(7):1255-60
23. Dieras V, Viens P, Veyret C, et al. Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): interim analysis of an open phase II label study. J Clin Oncol 2008;26(15 Suppl):1070
24. Zatloukal P, Gervais R, Vansteenkiste J, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol 2008;3(8):894-901
25. A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy. ClinicalTrials.gov identifier: NCT00081796
26. Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer. ClinicalTrials.gov identifier: NCT00625664
27. Larotaxel compared to continuous administration of 5-FU in advanced pancreatic cancer patients previously treated with a gemcitabine-containing regimen (PAPRIKA)ClinicalTrials.gov identifier: NCT00417209
28. Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996;24(2):153-72
29. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93(9):2325-7
30. Guenard D, Gueritte-Voegelein F, Dubois J, Potier P. Structure-activity relationships of Taxol and Taxotere analogues. J Natl Cancer Inst Monogr 1993;15:79-82
31. Blagosklonny MV. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia 1999;13(12):2031-5
32. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005;93(2):173-7
33. Brooks TA, Minderman H, O'Loughlin KL, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003;2(11):1195-205
34. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004;54(1):131-40; discussion 41-2
35. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25(16):2295-305
36. Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004;30(5):415-23
37. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972-7
38. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91(4):639-43
39. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13(6):1648-55
40. Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast (Edinburgh, Scotland) 2006;15(2):219-25
41. Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol (Stockholm, Sweden) 2006;45(2):196-201
42. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77